Pitolisant

Pitolisant
IUPAC ime
Drugi nazivi BF2.649
Identifikacija
CAS registarski broj 903576-44-3 DaY
PubChem[1][2] 9948102
ChemSpider[3] 8123714 DaY
ChEMBL[4] CHEMBL462605 DaY
Jmol-3D slike Slika 1
Svojstva
Molekulska formula C17H26ClNO
Molarna masa 295.85 g mol−1

 DaY (šta je ovo?)   (verifikuj)

Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala

Infobox references

Pitolisant (INN) ili tiprolisant (USAN) je inverzni agonist/antagonist histaminskog receptora koji je selektivan za H3 receptor.[5] On ima stimulantne i nootropne efekte u životinjskim studijama,[6] i može da ima nekoliko potencijalnih medicinskih primena. Istražen je za tretman narkolepsije, i za tu indikaciju mu je odobren status orfan leka u EU i SAD.[7][8] On je u kliničkim ispitivanjima za šizofreniju i Parkinsonova bolest.[8][9][10]

Pitolisant je razvijen nakon otkrića H3 receptora.[11] Pitolisant je prvi inverzni agonist H3 receptora sa kliničkom primenom.

Reference

  1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. ↑ Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ (December 2005). „Keynote review: histamine H3 receptor antagonists reach out for the clinic”. Drug Discov. Today 10 (23-24): 1613–27. DOI:10.1016/S1359-6446(05)03625-1. PMID 16376822. 
  6. ↑ Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC. BF2.649 [13-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. Journal of Pharmacology and Experimental Therapeutics. 2007 Jan;320(1):365-75. PMID 17005916
  7. ↑ Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiology of Disease. 2008 Apr;30(1):74-83. PMID 18295497
  8. ↑ 8,0 8,1 „Prous Science: Molecule of the Month September 2011”. Arhivirano iz originala na datum 2011-09-26. Pristupljeno 2014-04-11. 
  9. ↑ Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS, Burban A, Arrang JM, Schwartz JC. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochemical Pharmacology. 2007 Apr 15;73(8):1215-24. PMID 17343831
  10. ↑ Stocking EM, Letavic MA (2008). „Histamine H3 antagonists as wake-promoting and pro-cognitive agents”. Current Topics in Medicinal Chemistry 8 (11): 988–1002. DOI:10.2174/156802608784936728. PMID 18673168. 
  11. ↑ Schwartz, Jean-Charles. The histamine H3 receptor: from discovery to clincial trials with pitolisant. BPJ 2011 May [1]

Vanjske veze

Portal Hemija

Strategi Solo vs Squad di Free Fire: Cara Menang Mudah!